HopeStage
Back to all studies
CompletedNCT02260830

How Different Lu AF11167 Tablets Are Absorbed in the Body

About this titleRead the official source — NCT02260830
Medication studyAges 18–45United KingdomSchizophrenia
The study in practice

Understand this study

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Listed locations
NottinghamSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2014
Recruitment status
Completed
Enrollment listed in the registry
28
Sponsor
H. Lundbeck A/S
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United Kingdom
Age range
From 18 Years to 45 Years
Official registry ID
NCT02260830
Official title
Show the full official title

Interventional, Open-label, Part Fixed Sequence, Part-randomised Study Investigating the Pharmacokinetic Properties of up to 6 Prototype Modified Release Tablet Formulations of Lu AF11167 in Healthy Young Subjects

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Nottingham

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is H. Lundbeck A/S.

Did this study involve medication?

Yes. The study involved medication, including Lu AF11167.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies